Characterization of extracellular vesicle miRNA identified in peripheral blood of chronic pancreatitis patients
Characterization of extracellular vesicle miRNA identified in peripheral blood of chronic pancreatitis patients
复制标题
DOI：
10.1007/s11010-021-04248-5
复制
发表时间：
2021-08-27
影响因子：
4.3
通讯作者：
Maile, Robert
中科院分区：
文献类型：
--
作者：
Desai, Chirag S.;Khan, Aisha;Maile, Robert
血浆来源的细胞外囊泡（EV）可以作为细胞损伤/疾病的标志物，但也可以具有治疗效用，这取决于其货物（如miRNA）的性质。目前，在慢性胰腺炎（CP）患者管理的不同方面，早期诊断和治疗选择方面存在挑战和缺乏创新。使用EV作为胰腺健康的生物标志物和/或作为辅助治疗将使这些患者的管理有所不同。本研究的目的是表征从CP患者血浆中纯化的EV的miRNA货物，并与健康参与者的miRNA货物进行比较。从15名CP患者和10名健康对照的血浆中分离EV。纳米颗粒跟踪分析用于确定频率和大小，而NanoString技术用于表征miRNA货物。相关临床参数与EV miRNA货物相关。与健康个体相比，鉴定出约30种miRNA种类在患有CP的个体的EV中具有显著（p < 0.05）不同的表达;约40种miRNA在来自糖尿病前期与非糖尿病CP患者的EV中差异表达。miR-579- 3 p虽然在CP中表现出与健康相比显著更低（类似于16倍）的表达，并且在CP麻醉剂使用者中表现出与非使用者相比更低（类似于24倍）的表达，但与非糖尿病CP患者相比，miR-579- 3 p实际上在前驱糖尿病CP患者的EV中富集（类似于32倍）。在女性CP患者中发现了一种独特的模式。这些数据支持使用血浆来源的EV货物来评估胰腺健康及其在CP患者中的治疗潜力的前景。
Plasma-derived extracellular vesicles (EV) can serve as markers of cell damage/disease but can also have therapeutic utility depending on the nature of their cargo, such as miRNA. Currently, there are challenges and lack of innovations regarding early diagnosis and therapeutic options within different aspects of management of patients suffering from chronic pancreatitis (CP). Use of EV as biomarkers for pancreatic health and/or as adjuvant therapy would make a difference in management of these patients. The aim of this study was to characterize the miRNA cargo of EV purified from the plasma of CP patients and compared to those of healthy participants. EVs were isolated from plasma of 15 CP patients and 10 healthy controls. Nanoparticle tracking analysis was used to determine frequency and size, while NanoString technology was used to characterize the miRNA cargo. Relevant clinical parameters were correlated with EV miRNA cargo. similar to 30 miRNA species were identified to have significantly (p < 0.05) different expression in EV from individuals with CP compared to healthy individuals; similar to 40 miRNA were differentially expressed in EV from pre-diabetic versus non-diabetic CP patients. miR-579-3p, while exhibiting significantly lower (similar to 16-fold) expression in CP compared to healthy and lower (similar to 24-fold) in CP narcotic users compared to the non-users, is actually enriched (similar to 32-fold) within EV in pre-diabetic CP patients compared to non-diabetic CP patients. A unique pattern was identified in female CP patients. These data support the prospect of using a plasma-derived EV cargo to assess pancreatic health and its therapeutic potential in CP patients.